Bevacizumab in refractory gastrointestinal bleeding after liver transplant: An alternative for persistent Angiodysplasias

Gastrointestinal angiodysplasias are a frequent cause of recurrent bleeding, particularly challenging after liver transplantation when conventional therapies fail. We report a 43-year-old man with hepatitis C–related cirrhosis and recurrent gastrointestinal bleeding who continued to experience severe hemorrhages despite endoscopic therapy, vasoactive drugs, and thalidomide. Following liver transplantation, bleeding recurred, requiring repeated transfusions. Anti-angiogenic therapy with bevacizumab was initiated (5 mg/kg induction and consolidation cycles), leading to substantial reduction in bleeding episodes and transfusion needs. While more evidence is needed to define its role in standardized therapeutic algorithms, reports like this expand knowledge of bevacizumab use in non-oncologic settings.